Mareschal Julie, Hemmer Alexandra, Douissard Jonathan, Dupertuis Yves Marc, Collet Tinh-Hai, Koessler Thibaud, Toso Christian, Ris Frédéric, Genton Laurence
Clinical Nutrition, Service of Endocrinology, Diabetology, Nutrition and Therapeutic Education, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland.
Division of Abdominal Surgery, Department of Surgery, Geneva University Hospitals, 1205 Geneva, Switzerland.
Cancers (Basel). 2023 Mar 21;15(6):1881. doi: 10.3390/cancers15061881.
The advantages of prehabilitation in surgical oncology are unclear. This systematic review aims to (1) evaluate the latest evidence of preoperative prehabilitation interventions on postoperative outcomes after gastrointestinal (GI) cancer surgery and (2) discuss new potential therapeutic targets as part of prehabilitation. Randomized controlled trials published between January 2017 and August 2022 were identified through Medline. The population of interest was oncological patients undergoing GI surgery. Trials were considered if they evaluated prehabilitation interventions (nutrition, physical activity, probiotics and symbiotics, fecal microbiota transplantation, and ghrelin receptor agonists), alone or combined, on postoperative outcomes. Out of 1180 records initially identified, 15 studies were retained. Evidence for the benefits of unimodal interventions was limited. Preoperative multimodal programs, including nutrition and physical activity with or without psychological support, showed improvement in postoperative physical performance, muscle strength, and quality of life in patients with esophagogastric and colorectal cancers. However, there was no benefit for postoperative complications, hospital length of stay, hospital readmissions, and mortality. No trial evaluated the impact of fecal microbiota transplantation or oral ghrelin receptor agonists. Further studies are needed to confirm our findings, identify patients who are more likely to benefit from surgical prehabilitation, and harmonize interventions.
术前康复在外科肿瘤学中的优势尚不清楚。本系统评价旨在:(1)评估胃肠道(GI)癌手术后术前康复干预对术后结局的最新证据;(2)讨论作为术前康复一部分的新的潜在治疗靶点。通过Medline检索了2017年1月至2022年8月发表的随机对照试验。感兴趣的人群是接受GI手术的肿瘤患者。如果试验评估了术前康复干预(营养、体育活动、益生菌和共生菌、粪便微生物群移植和胃饥饿素受体激动剂)单独或联合使用对术后结局的影响,则纳入该试验。在最初识别的1180条记录中,保留了15项研究。单峰干预益处的证据有限。术前多模式方案,包括有或没有心理支持的营养和体育活动,显示食管癌和结直肠癌患者术后身体表现、肌肉力量和生活质量有所改善。然而,对术后并发症、住院时间、再次入院和死亡率并无益处。没有试验评估粪便微生物群移植或口服胃饥饿素受体激动剂的影响。需要进一步研究以证实我们的发现,确定更可能从手术前康复中获益的患者,并统一干预措施。